TG Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 11/28/2023

Stock Rating
9
Price Target
$24.00
Consensus
Outperform
Upside
90.02%
Analysts
1
Stock Rating
9
Upside
90.02%
Analysts
1
Price Target
$24.00

TG Therapeutics Stock Forecast and Price Target

The average price target for TG Therapeutics's stock set by recognized analysts recently is $24.00, which would result in a potential upside of approximately 90.02% if it reached this mark. The estimation is based on a high estimate of $41.00 and a low estimate of $6.00. If you're interested in TGTX stock, it's important to compare it to other companies in the industry.

$24.00

90.02% Upside

Outperform
Outperform

TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

TG Therapeutics's Price has grown In the last three years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $12.75 – an increase of 100.00%. For the next eight years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.

2023 Fair Value Forecast
$12.75
2024 Fair Value Forecast
$14.18
2025 Fair Value Forecast
$15.76
2026 Fair Value Forecast
$17.53
2027 Fair Value Forecast
$19.49
2028 Fair Value Forecast
$21.67
2029 Fair Value Forecast
$24.10
2030 Fair Value Forecast
$26.79
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NOVN Stock Forecast Novartis Outperform 9
CHF86.00 Buy/Sell CHF103.75 17.87%
SAN Stock Forecast Sanofi Outperform 13
85.76€ Buy/Sell 108.44€ 22.43%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$48.92 Buy/Sell $64.26 25.72%
MRK Stock Forecast Merck KGaA Buy 17
157.80€ Buy/Sell 204.63€ 18.19%
BAYN Stock Forecast Bayer Outperform 7
30.56€ Buy/Sell 55.86€ 60.34%

TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030

TG Therapeutics's Revenue has grown In the last three years, rising from $150.00k to $2.79M – a growth of 1760.00%. In the next year, analysts believe that Revenue will reach $229.47M – an increase of 8124.73%. For the next eight years, experts predict that TG Therapeutics's Revenue will grow at a rate of 61921.51%.

2023 Rev Forecast
$0.23B
2024 Rev Forecast
$0.25B
2025 Rev Forecast
$0.36B
2026 Rev Forecast
$0.70B
2027 Rev Forecast
$1.01B
2028 Rev Forecast
$1.36B
2029 Rev Forecast
$1.56B
2030 Rev Forecast
$1.73B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BIIB Stock Forecast Biogen Inc Outperform 11
$227.41 Buy/Sell $322.44 36.76%
GMAB Stock Forecast Genmab A/S Outperform 16
kr2.14k Buy/Sell kr2.84k 29.67%
TEVA Stock Forecast Teva Pharmaceutical Industries Hold 12
$9.80 Buy/Sell $12.04 9.69%

TG Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00

TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-176.18M – an increase of 32.53%. 3 analysts predict TG Therapeutics's Free Cash Flow will decrease by 122.15% in the next year, reaching $39.03M. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 573.89%, to $834.90M.

2023 FCF Forecast
$0.04B
2024 FCF Forecast
$0.01B
2025 FCF Forecast
$0.10B
2026 FCF Forecast
$0.29B
2027 FCF Forecast
$0.44B
2028 FCF Forecast
$0.64B
2029 FCF Forecast
$0.75B
2030 FCF Forecast
$0.83B

TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's Net Income has grown by 14.73%, rising from $-172.87M to $-198.34M. In the following year, 7 experts forecast that TG Therapeutics's Net Income will decrease by 105.05%, to $10.02M. In 2030, professionals predict that TG Therapeutics's Net Income will decrease by 644.19%, to $1.08B.

2023 NI Forecast
$0.01B
2024 NI Forecast
$0.00B
2025 NI Forecast
$0.07B
2026 NI Forecast
$0.30B
2027 NI Forecast
$0.50B
2028 NI Forecast
$0.80B
2029 NI Forecast
$0.95B
2030 NI Forecast
$1.08B

TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-192.54M. This represents a growth of 13.96%. For the following year, the 3 analysts predict that TG Therapeutics's EBITDA will drop by 104.12%, reaching $7.93M. Over the next eight years, experts predict that TG Therapeutics's EBITDA will grow at a rate of 32.66%.

2023 EBITDA Forecast
$0.01B
2024 EBITDA Forecast
$0.01B
2025 EBITDA Forecast
$0.02B
2026 EBITDA Forecast
$-178403796.00
2027 EBITDA Forecast
$-196267962.77
2028 EBITDA Forecast
$-236175781.87
2029 EBITDA Forecast
$-304651013.56
2030 EBITDA Forecast
$-255419409.77

TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030

TG Therapeutics's EBIT has seen growth In the last three years, going from $-169.06M to $-192.84M – a gain of 14.07% In the following year, the 8 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 106.58%, reaching $12.69M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 688.99%, falling down to $1.14B.

2023 EBIT Forecast
$0.01B
2024 EBIT Forecast
$0.00B
2025 EBIT Forecast
$0.08B
2026 EBIT Forecast
$0.34B
2027 EBIT Forecast
$0.59B
2028 EBIT Forecast
$0.87B
2029 EBIT Forecast
$1.02B
2030 EBIT Forecast
$1.14B

TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's EPS has gone down from $-1.96 to $-1.46 – a 25.51% drop. In the next year, 7 analysts estimate that TG Therapeutics's EPS will decrease by 101.37%, reaching $0.02. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 539.73%, reaching $6.42.

2023 EPS Forecast
$0.02
2024 EPS Forecast
$0.02
2025 EPS Forecast
$0.48
2026 EPS Forecast
$1.69
2027 EPS Forecast
$2.92
2028 EPS Forecast
$4.77
2029 EPS Forecast
$5.67
2030 EPS Forecast
$6.42